

DESCRIPTION

Source *E. coli*-derived mouse TDO2 protein
Val18-Phe388
Accession # P48776
with a C terminal 6-His tag

N-terminal Sequence Analysis Val18

Predicted Molecular Mass 45 kDa

SPECIFICATIONS

SDS-PAGE 39 & 75 kDa, reducing conditions

Activity Measured by its ability to oxidize L-tryptophan to N-formyl-kynurenine.
The specific activity is >500 pmol/min/μg, as measured under the described conditions.

Endotoxin Level <0.10 EU per 1 μg of the protein by the LAL method.

Purity >90%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie® Blue Staining.

Formulation Supplied as a 0.2 μm filtered solution in Tris, NaCl and Glycerol. See Certificate of Analysis for details.

Activity Assay Protocol

- Materials**
- Assay Buffer: 50 mM MES, pH 6.5
 - 0.405 M Tris, pH 8.0
 - Recombinant Mouse TDO2 (rmTDO2) (Catalog # 10001-TD)
 - Ascorbic Acid (Sigma, Catalog # 255564), 500 mM stock in deionized water
 - L-Tryptophan (Sigma, Catalog # T0254), 40 mM stock in deionized water
 - Catalase (Sigma, Catalog # C30), 100,000 Units/mL stock in Assay Buffer
 - Methylene Blue (Sigma, Catalog # 28514), 10 mM stock in deionized water
 - 96-well Clear Plate (Catalog # DY990)
 - Plate Reader (Model: SpectraMax Plus by Molecular Devices) or equivalent

- Assay**
1. Prepare Substrate Mixtures.
 - a. Dilute L-Tryptophan to 8 mM in Assay Buffer
 - b. Dilute Ascorbic acid to 80 mM in 0.405 M Tris, pH 8.0.
 - c. Prepare a mixture of 9000 Units/mL catalase, and 40 μM Methylene Blue in Assay Buffer.
 - d. Mix equal volumes of 1b and 1c for final concentrations of 40 mM Ascorbic Acid, 4500 units/mL Catalase, and 20 μM Methylene Blue.
 2. Dilute rmTDO2 to 40 ng/μL in Assay Buffer.
 3. Load 25 μL of 40 ng/μL rmTDO2 to clear plate, and start the reaction by adding 25 μL of 8 mM L-Tryptophan followed by 50 μL of Mixture 1d. Include a Substrate Blank containing 25 μL Assay Buffer, 25 μL 8 mM L-Tryptophan and 50 μL of Mixture 1d.
 4. Read plate in kinetic mode for 5 minutes at an absorbance of 321 nm.
 5. Calculate specific activity:

$$\text{Specific Activity (pmol/min/}\mu\text{g)} = \frac{\text{Adjusted } V_{\text{max}}^* (\text{OD/min}) \times \text{well volume (L)} \times 10^{12} \text{ pmol/mol}}{\text{ext. coeff}^{**} (\text{M}^{-1}\text{cm}^{-1}) \times \text{path corr.}^{***} (\text{cm}) \times \text{amount of enzyme } (\mu\text{g})}$$

*Adjusted for Substrate Blank.

**Using the extinction coefficient 3750 M⁻¹cm⁻¹.

***Using the path correction 0.32 cm.

Note: the output of many spectrophotometers is in mOD.

- Final Assay Conditions**
- Per Well:
- rmTDO2: 1.0 μg
 - Ascorbic Acid: 20 mM
 - L-Tryptophan: 2 mM
 - Catalase: 225 units
 - Methylene Blue: 10 μM


PREPARATION AND STORAGE

Shipping The product is shipped with dry ice or equivalent. Upon receipt, store it immediately at the temperature recommended below.

- Stability & Storage** Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
- 6 months from date of receipt, -20 to -70 °C as supplied.
 - 3 months, -20 to -70 °C under sterile conditions after opening.


DATA

Enzyme Activity



Recombinant Mouse TDO2 (Catalog # 10001-TD) is measured by its ability to oxidize L-tryptophan to N-formyl-kynurenine.

SDS-PAGE



1 µg/lane of Recombinant Mouse TDO2 was resolved with SDS-PAGE under reducing (R) and non-reducing (NR) conditions and visualized by silver staining, showing bands at 39 kDa and 75 kDa under R conditions.

BACKGROUND

Tryptophan 2,3-dioxygenase (TDO2), a heme-containing cytosolic dioxygenase, forms a homo-tetrameric active molecule of approximately 190 kDa composed of 48 kDa monomers (1, 2). Mouse TDO2 shares 89% aa sequence identity with human TDO2. TDO2 is one of three proteins capable of catalyzing the first and rate-limiting step of the L-kynurenine pathway (KP): oxidative cleavage of the essential amino acid L-tryptophan to form N formyl kynurenine (3). TDO2 is a cytosolic protein typically localized to the liver and brain, unlike the more ubiquitously expressed indoleamine 2,3-dioxygenase (IDO), yet it is responsible for ~90% of the primary route of catabolism of tryptophan through the KP (3). TDO2 is upregulated in extrahepatic tumors (4-6) and is consequently a target in cancer immunotherapy (7). TDO2 is a therapeutic target in brain disease such as schizophrenia, Alzheimers disease, multiple sclerosis and glioma (8-11) due to its role in the regulation of levels of critical biologically active downstream KP metabolites (3). Polymorphisms in the TDO2 gene have been implicated for a role in behavioural responses and autism (12,13).

References:

1. Lewis-Ballester, A. *et al.* (2016) *Sci. Rep.* **6**:35169.
2. Rafice, S.A. *et al.* (2009) *Biochem. Soc. Trans.* **37**:408.
3. Badawy, A. (2017) *Int J. Tryptophan Res.* **10**:1.
4. Pilotte, L. *et al.* (2012) *Proc. Natl. Acad. Sci. U.S.A.* **109**:2497.
5. D'Amato, N.C. *et al.* (2015) *Cancer Res.* **75**:4651.
6. Yu, C.P. *et al.* (2017) *Med. Oncol.* **34**:73.
7. Platten, *et al.* (2015) *Front. Immunol.* **5**:673.
8. Breda, C. *et al.* (2016) *Proc. Natl. Acad. Sci. U.S.A.* **113**:5435
9. Yu, C.P. *et al.* (2016) *Metab. Brain Dis.* **31**:737.
10. Lanz, T.V. *et al.* (2017) *Sci. Rep.* **7**:41271.
11. Reus, G.Z. *et al.* (2018) *Prog. Neuropsychopharmacol. Biol. Psychiatry* **81**:55.
12. Soichot, M. *et al.* (2013) *Alcohol Alcohol* **48**:415.
13. Nabi, R. *et al.* (2004) *Am. J. Med. Genet. B. Neuropsychiatr. Genet.* **125B**:63.